Company: BIAF
Filing Date: 2025-04-15
Form Type: DRS
Source: 0001641172-25-004915
Chunk: 12

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: DRS
Chunk 12
---
 Offering

| ● | Our                                                                                        
 management will have broad discretion over the use of the net proceeds from this offering. |

| ● | You                                                                                               
 may experience dilution in the net tangible book value per share of the Common Stock issued       
 in this offering or that may be issued upon the exercise of any warrants issued in this offering. |

| ● | Future                                                                                       
 issuances of our Common Stock or rights to purchase Common Stock, could result in additional 
 dilution of the percentage ownership of our stockholders and could cause our stock price     
 to fall.                                                                                     |

| ● | If                                                                                        
 we issue additional securities it could adversely affect the rights of the holders of our 
 Common Stock.                                                                             |

| ● | We                                                                                        
 may not raise the amount of capital we believe is required for our business plans in this 
 offering.                                                                                 |

| ● | Investors                                                                                
 in this offering will not receive a refund in the event that we do not sell an amount of 
 securities sufficient to pursue the business goals outlined in this prospectus.          |

| ● | Purchasers                                                                                         
 of our securities in this offering pursuant to a securities purchase agreement may have additional 
 rights.                                                                                            |

| ● | There                                                                   
 is no public market for the April 2025 Warrants or Pre-Funded Warrants. |

| ● | The                                                             
 April 2025 Warrants in this offering are speculative in nature. |

| ● | Holders                                                                                        
 of warrants purchased in this offering will not have rights of holders of our shares of Common 
 Stock until exercised.                                                                         |

| ● | The                                                                                      
 April 2025 Warrants may not be exercisable until we obtain Warrant Stockholder Approval. |

| ● | If                                                                                         
 we do not maintain a prospectus relating to the Common Stock issuable upon exercise of the 
 April 2025 Warrants and Pre-Funded Warrants, public holders will only be able to exercise  
 on a “cashless basis.”                                                                     |

| ● | We                                                     
 may be required to repurchase the April 2025 Warrants. |

Risks Related to our Diagnostic Product

| ● | The                                                                                 
 FDA could impose greater regulatory burdens on laboratory developed tests (“LDTs”). |

| ● | Delays                                                                                     
 or difficulties in the enrollment of patients could delay or prevent regulatory approvals. |

| ● | Clinical                                                         
 trials are expensive, time-consuming, and may not be successful. |

Risks Related to Our Diagnostic Tests

| ● | If                                                                                         
 our tests do not perform